The Federal State Unitary Enterprise Moscow Endocrine Plant (FSUE Endopharm) is under the jurisdiction of the Ministry of Industry and Trade of the Russian Federation and is one of the key manufacturers of vital and socially significant drugs in the country.
The company has more than 80 years of successful history in the development and production of drugs, from the manufacture of pharmaceutical substances to the release of finished dosage forms.
The product portfolio of FSUE Endopharm includes about 150 names of drugs, most of which are included in the list of vital and essential drugs approved by the Government of the Russian Federation.
A significant share of drugs is made up of centrally acting analgesics, as well as drugs widely used in ophthalmology, cardiology, gynecology and psychoneurological practice, anti-inflammatory and metabolic drugs, and a number of others.
The Company's products are in high demand in all regions of Russia and in 13 foreign countries.
